Advertisement
Advertisement
SRZN
Surrozen, Inc. Common
26.37
USDSponsored
-0.72
-2.66%
May 22, 15:59 UTC -4
Closed
Pre-Market
26.23
-0.14
-0.51%
SRZN Earnings Reports
Positive Surprise Ratio
SRZN beat 9 of 18 last estimates.
50%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Surrozen, Inc. Common earnings per share and revenue
On May 06, 2026, SRZN reported earnings of -11.65 USD per share (EPS) for Q1 26, missing the estimate of -1.11 USD, resulting in a -945.97% surprise. Revenue reached 5.00 million, compared to an expected 4.08 million, with a 22.55% difference. The market reacted with a -9.90% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
Marker Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.44%
PLUS THERAPEUTICS, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.89
Actual
-$1.05
Surprise
-16.98%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
Vivos Therapeutics, Inc. Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.46
Actual
-$0.52
Surprise
-12.46%
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
Cosmos Holdings Inc. Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.01
Actual
-$0.06
Surprise
-488.24%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
What were Surrozen, Inc. Common's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Surrozen, Inc. Common reported EPS of -$11.65, missing estimates by -945.97%, and revenue of $5.00M, 22.55% above expectations.
How did the market react to Surrozen, Inc. Common's Q1 2026 earnings?
The stock price moved down -9.9%, changed from $34.13 before the earnings release to $30.75 the day after.
When is Surrozen, Inc. Common expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Surrozen, Inc. Common's next earnings report?
Based on --
analysts, Surrozen, Inc. Common is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement